ISpecimen Correlations
ISPC Stock | USD 1.66 0.05 3.11% |
The correlation of ISpecimen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
ISpecimen Correlation With Market
Good diversification
The correlation between iSpecimen and DJI is -0.07 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding iSpecimen and DJI in the same portfolio, assuming nothing else is changed.
ISpecimen |
Moving together with ISpecimen Stock
0.7 | ILMN | Illumina Sell-off Trend | PairCorr |
0.78 | INZY | Inozyme Pharma | PairCorr |
0.83 | KURA | Kura Oncology | PairCorr |
0.95 | ABOS | Acumen Pharmaceuticals | PairCorr |
0.94 | ADTX | Aditxt Inc | PairCorr |
0.84 | STRO | Sutro Biopharma | PairCorr |
0.92 | TCRX | Tscan Therapeutics | PairCorr |
0.84 | TERN | Terns Pharmaceuticals | PairCorr |
0.89 | CRNX | Crinetics Pharmaceuticals Buyout Trend | PairCorr |
0.73 | CTMX | CytomX Therapeutics | PairCorr |
0.7 | DAWN | Day One Biopharmaceu | PairCorr |
0.74 | TLKMF | Telkom Indonesia Tbk | PairCorr |
Moving against ISpecimen Stock
0.79 | OPT | Opthea | PairCorr |
0.71 | LTRN | Lantern Pharma | PairCorr |
0.7 | PHGE | Biomx Inc | PairCorr |
0.69 | FENC | Fennec Pharmaceuticals | PairCorr |
0.67 | GANX | Gain Therapeutics | PairCorr |
0.6 | PFE | Pfizer Inc | PairCorr |
0.57 | CUE | Cue Biopharma | PairCorr |
0.63 | DBVT | DBV Technologies Earnings Call This Week | PairCorr |
0.55 | CGTX | Cognition Therapeutics | PairCorr |
0.37 | CPRX | Catalyst Pharmaceuticals | PairCorr |
0.88 | OBI | Ondine Biomedical | PairCorr |
0.85 | SSNLF | Samsung Electronics | PairCorr |
0.74 | GPI | Group 1 Automotive | PairCorr |
0.71 | EC | Ecopetrol SA ADR Sell-off Trend | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ISpecimen Stock performing well and ISpecimen Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ISpecimen's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
GTH | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
OLK | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
FONR | 1.26 | (0.13) | 0.00 | (0.24) | 0.00 | 2.50 | 10.83 | |||
CSTL | 2.26 | (0.38) | 0.00 | 14.85 | 0.00 | 3.79 | 23.12 | |||
XGN | 5.13 | 0.18 | 0.02 | 0.05 | 6.44 | 15.86 | 45.67 | |||
OCX | 2.84 | 0.15 | 0.05 | 0.52 | 2.88 | 7.56 | 23.66 | |||
PSNL | 5.48 | 0.67 | 0.11 | 0.16 | 5.18 | 9.82 | 60.83 | |||
IDXG | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
TRIB | 5.35 | (0.35) | 0.00 | (1.35) | 0.00 | 11.25 | 108.49 | |||
HTGM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ISpecimen Corporate Management
Emily Hubbard | VP Devel | Profile | |
Benjamin Bielak | Chief Secretary | Profile | |
Eric Langlois | Chief Officer | Profile | |
Dawn Michelle | VP Operations | Profile | |
Yuying Liang | Chief Officer | Profile | |
Annette Arnold | Vice Development | Profile |